- Research article
- Open Access
The cardioprotective effect of danshen and gegen decoction on rat hearts and cardiomyocytes with post-ischemia reperfusion injury
BMC Complementary and Alternative Medicine volume 12, Article number: 249 (2012)
Danshen (Salviae Miltiorrhizae Radix) and Gegen (Puerariae Lobatae Radix) have been used for treating heart disease for several thousand years in China. It has been found that a Danshen and Gegen decoction (DG) exhibiting an anti-atherosclerosis effect, which improves the patients’ heart function recovery. Pre-treatment with DG was reported to have protective effects on myocardium against ischemia/reperfusion injury. In the present study, we aim to investigate the post-treatment effect of DG on ischemic-reperfusion injuries ex vivo or in vitro and the underlying mechanisms involved.
The rat heart function in an ischemia and reperfusion (I/R) model was explored by examining three parameters including contractile force, coronary flow rate and the release of heart specific enzymes within the heart perfusate. In vitro model of hypoxia and reoxygenation (H/R), the protective effect of DG on damaged cardiomyocytes was investigated by examining the cell structure integrity, the apoptosis and the functionality of mitochondria.
Our results showed that DG significantly improved rat heart function after I/R challenge and suppressed the release of enzymes by damaged heart muscles in a dose-dependent manner. DG also significantly inhibited the death of cardiomyocytes, H9c2 cells, with a H/R challenge. It obviously decreased cell apoptosis, protected the mitochondrial function and cell membrane skeleton integrity on H9c2 cells. The cardio-protection was also found to be related to a decrease in intracellular calcium accumulation within H9c2 cells after I/R challenge.
The potential application of DG in treating rat hearts with an I/R injury has been implied in this study. Our results suggested that DG decoction could act as an anti-apoptotic and anti-ion stunning agent to protect hearts against an I/R injury.
The myocardial tissue is typically aerobic and its metabolism is closely dependent upon oxygen availability which is confirmed by the abundance of mitochondria and myoglobin in the cardiomyocytes. In addition, the high-energy requirement of cardiomyocytes for its contraction is met almost exclusively by mitochondrial oxidative phosphorylation. This, in turn, leads to the high sensitivity of myocardial cells to oxygen deficiency. Once the blood flow to the myocardial tissue is blocked and the oxygen shortage environment (ischemia) is subsequently induced, serious cardiac damage will happen in the ischemic region for the decrease of energy supply and acidosis inducing by anaerobic glycolysis[3, 4], the notable decrease of intracellular pH value and the increase of intracellular calcium ion concentration ([Ca2+ i)[5–7]. Clinically, there are obviously increasing release of heart damage enzyme markers (creatine kinase and lactate dehydrogenase) in the serum of patients with myocardial ischemic injury. Additionally, the decrease contractile force or ventricular akinesis for the myocardium damage disturbs the normal blood circulation, which intensifies the heart tissue injury[1, 9]. In this case, a series of cardiac injury events will happen, such as a decrease in the energy-supplying substances (such as ATP, phocereatin and glycogen), an increase in lactate production and acidosis for anaerobic glycolysis[6, 7], an accumulation of the substrates for generating superoxide (O2 -) and hydrogen peroxide, a notable decrease of the intracellular pH value and an increase of intracellular calcium ion concentration ([Ca2+ i)[5–7]. Although the restoration of blood supply in the ischemic region is essential for salvage of myocardium, the accompanying reperfusion during the first few minutes can induce worse effect on myocardium rather than improve its dysfunction. This procedure is called post-ischemic reperfusion injury, which is characterized by the sharp production of superoxide and other reactive oxygen species (ROS), extreme exacerbation of the ionic disturbances (such as, Ca2+) in the cytosol and mitochondria. These can induce peroxidation of membrane lipid, denaturation of the proteins on ion channels and cytoskeleton proteins (such as, Troponin I, which is also a myo-contractile factor) (including enzymes and ion channels) as well as the breaking-down of DNA[8, 11, 12]. Increased production of ROS and the accumulation of calcium in the cytosol and mitochondria are considered to be two major causative factors involving this injury[13, 14]. They also could induce the damage of mitochondria (such as, the opening of the mitochondrial permeability transition pore, mPTP), which then triggers itself depolarization, more mitochondrial ROS generation, and intense cell demisemore cytochrome c release from mitochondria into cytosol[15, 16]. Those damage-related factors can directly initiate the myocardium apoptosis pathway to intense cell dysfunction and demise[12, 16].
Traditional Chinese medicine (TCM) has the benefit of multi-targeting and synergism, which features have been widely used in China to treat heart diseases. Among them, Danshen and Gegen are commonly present in herbal formulae for treating human heart diseases. Chemical Danshen is the dried root of Salviae miltiorrhizae and it can be divided into lipophilic and hydrophilic fractions. The main active components of its hydrophilic fraction are salvianolic acid B, danshensu, protocatechuic acid, and rosmarinic acid[18–20]. Some research groups have shown that the water extraction of Danshen decreased the infarct size and protected the mitochondrial membrane function in rat hearts which had an I/R injury[21–23]. Gegen is the dried root of Pueraria lobata. The chemical constituents of Gegen are mainly isoflavonoids, such as puerarin, diadzin, daidzein, 8-C-apiosylglucoside, genistin and genistein[24, 25]. The components puerarin, daidzin and diadzein have been found to exert cardiovascular protection by inhibiting platelet aggregation and decrease of serum cholesterol[26–28].
In our previous studies, a Danshen and Gegen decoction (DG) in the ratio of 7 to 3 (w/w) was found to exert anti-atherosclerotic property to protect cardiovascular system both in clinical and pre-clinical studies[29, 30]. Especially, pretreatment of DG inhibited the oxidation stress in the rat heart with ischemia/reperfusion injury by increasing the activity of PKC pathway and improved the heart function recovery[31, 32]. In the present study, and I/R rat heart model and an hypoxia and reperfusion (H/R) cellular model have been applied to examine whether DG exert a cardiac protective effect against ischemic reperfusion injury. Our findings could provide evidence that DG would be a useful decoction for treating patients who are undergoing cardiac surgery and thrombolytic therapy which are usually accompanied with ischemic reperfusion injury.
Herbal extract and chemicals
The raw herbs of Danshen and Gegen were purchased from the herbal shops in Sichuan and Guangdong province, respectively. The herbal extraction was carried out by National Engineering Research Center for Modernization of Traditional Chinese Medicine, a GMP compliance manufacturer in the People’s Republic of China. The quantification of the major components in DG decoction was conducted in accordance with our previous study. A small quantity of the two raw herbs were deposited as voucher specimen in the museum of the Institute of Chinese Medicine in The Chinese University of Hong Kong, with voucher specimen number of 2008-3166a and 2008-3167a for Danshen and Gegen, respectively. Same batch of DG decoction was used throughout the experiment in our present study. Unless otherwise specified, the chemicals used in this study were purchased from Sigma-Aldrich Chemical Company. KB-R 7943 was purchased from Tocris Bioscience (USA).
H9c2 cells are an adherent rat cardiac cell line with myoblast morphology. These cells were obtained from American Tissue Culture Collection (Manassas, VA) and cultured in DMEM with 10% FBS and 1% PS.
Ischemia and reperfusion Langendorff heart model
220–250 g Male Sprague–Dawley (SD) rats were supplied by Laboratory Animal Sciences Center (LASEC) of The Chinese University of Hong Kong (CUHK). All experimental protocols were approved by the Animal Experimental Ethics Committee (AEEC) at the CUHK. The rats were killed by cervical dislocation and their hearts were excised within one minute thereafter. The hearts were then put into cold heparinized Kreb’s solution (4.7 mM KCl, 2.5 mM CaCl2, 1.2 mM MgSO4, 1 mM KH2PO4, 11 mM glucose, 25 mM NaHCO3 at pH 7.4) with 50 unit/ml heparin to prevent blood clotting. The surrounding connective tissues and fats were removed. The aorta of each rat heart was then cannulated on a Langendorff apparatus. The heart was then perfused with Kreb’s solution (gassed with 95% O2, 5% CO2) and enclosed in a 37°C pre-warmed organ bath. A basal force of 2 g was then applied to these rat hearts. After equlibrated for 20 min, the supply of Kreb’s solution was stopped for 30 min (ischemia). At the last minute of ischemia, 200 μl of DG solution which contained 0.4 mg or 1.6 mg of DG extract (dissolved in Kreb’s solution) or trolox (20 μM) were injected into the rat heart through its aorta before reperfusion. Reperfusion was then started and lasted for 15 min. Kreb’s solution was used instead of DG for the control group. Various parameters were measured at 10th min and 20th min during the equilibration as the normalizing parameter and every minute during the 15-min reperfusion.
Measurement of contractile force
The contractile force was determined by a wire which was connected to a force- displacement transducer. The force-displacement transducer (Power lab/8sp, AD Instruments) was connected to a Powerlab and the force was translated into a digital signal. The recording rate was set at 1 K/s. The percentage contractile force recovery was the contractile force in every minute during reperfusion when compared to the average values at 10th min and 20th min of equilibration.
Measurement of coronary flow rate
The amount of the coronary heart perfusate was collected and measured at 1 min interval for 15 min. It was assumed that the density of the heart perfusate was about 1 g/ml (which is the same as water). The weight of the heart perfusate collected in 1 min was the average flow rate (ml/min). The percentage coronary flow rate recovery was the coronary flow rate in each minute during reperfusion as compared to the average values at 10th min and 20th min of equilibration.
Measurement of creatine kinase (CK) and lactate dehydrogenase (LDH) activity
Coronary heart perfusate were placed on ice after weighing until they were assayed for creatine kinase (CK) and lactate dehydrogenase (LDH) activity. The extent of CK and LDH leakage during the reperfusion period, as an indication of myocardial injury, was estimated by the percentage of CK and LDH accumulative activity at each minute of the reperfusion time (1–15 minutes). In the present study, the CK and LDH content were measured by commercially available kits (Stanbio Laboratory, USA). For measuring CK activity, 20 μl of the heart perfusate were added to 30°C pre-warmed cuvette containing 1 ml CK reagent and mixed by inversion. After 3 min incubation, the absorbance was read at 340 nm, versus water as a reference. Absorbance was measured at 30-second intervals for a period of 120 seconds. The activity of CK in U/l is the change of absorbance per minute (ΔA/min).
For LDH measurement, 50 μl of the heart perfusate was added to 30°C pre-warmed cuvette containing 1 ml CK reagent and mixed by inversion. After 3 min incubation, the absorbance was read at 340 nm versus water as a reference. Absorbance was read at 10-second intervals for a period of 60 seconds. The activity of LDH in U/l is the change of absorbance per minute (ΔA/min).
Hypoxia and reoxygenation cardiomyocytes model
Hypoxia and reoxygenation (H/R) on H9c2 cells were performed as described with minor modifications[35, 36]. After seeding the cells overnight, the culture medium was replaced by a salt balance solution for 1 hour to synchronize the cells in each group. Hypoxia medium (bubbled with N2 for 30 min) was then added to replace the salt balance solution. The plate was then put into a hypoxia chamber and incubated at 37°C with the oxygen removed. After 12 hours incubation, the hypoxia medium was substituted by normal medium with or without DG and the cells were incubated for another 4 hours before performing various assays.
Determination of the viability of H9c2 cells in a normoxic situation with a H/R injury
H9c2 cells (6 × 103/well) were seeded on 96-well plate and incubated overnight. In normoxic environment, the cells were treated with DG for 24 hours. In H/R injury situation, the cells were firstly challenged with hypoxia for 12 h and were then treated with or without DG (125 μg/ml and 250 μg/ml) or trolox (20 μM as positive control) for 4 hours in a reoxygenation phase. Cell viability was then measured by MTT assay by adding 30 μl of MTT solution (5 mg/ml) to each well, which were then incubated at 37°C, 5% CO2 humidified incubator for 4 h. After that, 50 μl of dimethyl sulfoxide (DMSO) was added to dissolve the crystals. Absorbance at 540 nm was finally measured by using a microplate reader.
Determination of cell apoptosis with Annexin V-FITC and PI double staining
H9c2 cells (3 × 105/well) were seeded in a 6-well plate and were then incubated overnight. After hypoxia and reoxygenation treatment, the cells were collected by trypsization, washed with PBS and then resuspended in 250 μl of binding buffer (10 mM HEPES, 150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, pH 7.4). A 250 μl reaction binding buffer containing Annexin V-FITC PI was then added to the resuspended cells. The cells were kept on ice throughout the experiment. The mixture was kept at room temperature in the dark. After 15 min incubation, cell apoptosis was analyzed by FACSCanto flow cytometer (Becton Dickinson).
Measurement of mitochondrial depolarization
H9c2 cells (3 × 105/well) were seeded in 6-well plate and incubated overnight. After hypoxia and reoxygenation treatment, the cells were collected by trypsization, washed with PBS and then resuspended in JC-1 solution (10 μM in PBS). The cells were then incubated in 37°C for 15 min in dark and were finally analyzed by a FACSCanto flow cytometer (Becton Dickinson).
Measurement of calcium localization in H9c2 cells
H9c2 cells were seeded into a confocal culture dish (3 × 105). After overnight incutbation, the cells were then incubated with an ischemia medium containing Fluo-4 AM solution (5 μM in PBS). After 12 h, the ischemia medium was replaced by Fluo-3 medium (140 mM NaCl, 5 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM glucose, 10 mM HEPES, pH 7.4) with or without DG (125 μg/ml and 250 μg/ml) or KB-R 7943 (10 μM as positive control). Calcium signal was measured for 15 min under confocal microscope (Olympus, Japan) with an excitation wavelength of 488 nm and a light emission of 520 nm.
Western blotting analysis
Total cellular protein was used for detecting caspase 3, bcl 2 and Troponin I expressions. Mitochondrial and cytosolic proteins were used for detecting the distribution of cytochrome c in these cellular fractions. An equal amount of protein (30 μg) was resolved by 8% or 12% SDS-polyacrylamide electrophoresis gel. The resolved proteins were transferred to a PDVF-membrane. After blocking with 5% non-fat milk for 60 min, the blots were incubated overninght at 4°C with respective antibodies: anti-caspase 3 (1:1000, Cell Signaling, USA, Cat # 9662), anti-bcl 2 (1:1000, Cell Signaling, USA, Cat # 2870), anti-Tropinin I (1:1000, Cell Signaling, USA, Cat # 4002), anti-cytochrome c (1:1000, Cell Signaling, USA, Cat # 4272), COX-IV (1:1000, Cell Signaling, USA, Cat # 4844) and β-actin (1:10000, Sigma-Aldrich, USA, Cat # A2228). Anti-rabbit HRP conjugated IgG (1:1000, Invitrogen, USA, Cat # 65–6120) and anti-mouse HRP-conjugated IgG (1:1000, Invitrogen, USA, Cat # 62–6520) were used to detect the binding of their corresponding antibodies by incubating for 2 h at room temperature. The resolved protein was then visualized by developing the image on a film using ECL Western Blotting Detection Reagents (GE Healthcare, UK).
The results were expressed as a mean ± S.E.M. The statistical differences between groups were analyzed by One-way or Two-way ANOVA followed by a Bonferroni post-hoc test. All tests were carried out at 5% level of significance (two-tailed, p < 0.05).
Effects of DG decoction on cardiac function recovery and damage-related enzyme release
In Figure 1A, low dosage of DG (0.4 mg/200 μl) showed a small but significant improvement on the contractile force recovery when compared to the control group. The contractile force recovery percentage was 35% and 23% in low dosage of DG and in control group, respectively. Obvious protection was shown when the dosage of DG was increased to 1.6 mg/200 μl, where the recovery at the last minute of reperfusion was 66%.
As shown in Figure 1B, 2 mg/ml of DG improved the coronary flow rate without a significant difference as compared to the control group. The recovery percentages at the end point was 64% and 53%, respectively. At high dosage of DG, the recovery was noticeably increased to 102% at the end of the reperfusion. A similar effect was observed in the positive control of trolox, which significantly improved the coronary flow rate to 82%.
As shown in Figure 1C, low dosage of DG did not show any obvious protection against CK leakage (11.86 U/l), which was similar to that in the control group (13.61 U/l). However, there was significant protection against CK leakage at a high dosage of DG (6.17 U/l), when compared to that in control group. Trolox had similar protection as high dosage group which reduced the CK release significantly.
Figure 1D showed LDH release in each group. Low dosage DG group did not show significant protection against LDH release (3.98 U/l), which was similar to that in control group (4.55 U/l). At high dosage, there was a significant reduction of LDH release (3.32 U/l) when compared to that in control group. LDH release for the trolox-treated group (3.64 U/l) was similar to that of high dosage DG group.
Effect of DG decoction on H9c2 cell survival after a H/R challenge
The survival of H9c2 cells after a H/R-challenge was assessed by MTT assay (Figure 2). It was found that H/R treatment significantly reduced cell viability to 38.74% when compared to the normal control (no H/R treatment). The viability of H9c2 cells with H/R-challenge was significantly increased to 48.19% and 54.92% at 125 and 250 μg/ml DG treatment, respectively (p < 0.05 and p < 0.001). The effect of DG was similar to that of trolox which increased cell viability to 50.46% (p < 0.01).
Effect of DG decoction on membrane skeleton integrity of H9c2 cells
To explore the cell membrane skeleton integrity, Troponin I expression was analyzed by Western blotting. As shown in Figure 3, the relative amount of the Troponin I in DG-treated cells (250 μg/ml) was upregulated from 100% to 117.5% when compared to control. The relative amount of Troponin I was 124.3% in a normoxia group and 115.9% in trolox-treated cells with a H/R challenge (p < 0.01 and p < 0.05, respectively).
Effect of DG decoction on apoptosis induction in H9c2 cells after a H/R challenge
As shown in Figure 4, DG significantly inhibited the early apoptosis of H9c2 cells which was induced by a H/R challenge and the percentage of early apoptotic cells number was reduced from 22.87% (control) to 9.73% and 10.67% in the 125 μg/ml and 250 μg/ml DG-treated group, respectively (p < 0.05 and p < 0.01). The percentage of early apoptotic cells in normaxic and trolox-treated group were 2.37% and 7.4%, respectively (p < 0.001and p < 0.01). High concentration of DG (250 μg/ml) was also found to significantly decrease the late apoptosis of H9c2 cells with H/R injury (p < 0.05).
To further investigate the underlying mechanism, the expression level of caspase 3 and bcl 2 were investigated. As shown in Figure 5A, the relative expression of caspase 3 was significantly decreased to 91.3% in 250 μg/ml DG treated-group as compared to the control (set as 100%). Bcl 2 expression was increased at both DG concentrations (125 and 250 μg/ml) by about 10% (p < 0.05 and p < 0.01, respectively), which was similar to the normaxic group and the trolox-treated group (p < 0.01 and p < 0.05).
Effect of DG decoction on cytochrome c release from mitochondria of damaged H9c2 cells
Figure 5B showed that cytochrome c release from mitochondria to cytosol was decreased in a dose-dependent manner in DG-treated groups. For cytosolic fraction, similar to the positive control, the relative amount of cytochrome c was 87.5% in DG (250 μg/ml) treated group (p < 0.05). On the other hand, in mitochondria, the value of cytochrome c expression was significantly increased by about 7% and 16% in high concentration of DG-treated group and trolox-treated groups, respectively (p < 0.05).
Effect of DG decoction on mitochondrial depolarization in H9c2 cells after H/R challenge
As shown in Figure 6, H/R treatment induced the depolarization of mitochondrial membrane potential of H9c2 cells from 3.6% (normal) to 13.77% (control). Mitochondria depolarization significantly decreased to 9.43% and 8.26% in 125 μg/ml and 250 μg/ml DG-treated groups, respectively (p < 0.05 and p < 0.01) and to 9.84% in trolox-treated group (p < 0.001).
Effect on calcium accumulation within H9c2 cells after a H/R challenge
Figure 7A showed a representative figure on accumulative calcium signal. It was shown that the calcium signal was induced in H9c2 cells with H/R challenge and the increase was suppressed by DG treatment or KB-R 7943 treatment (positive control). The relative accumulated calcium in normal H9c2 cells was 66.15%. After H/R-challenge, DG treatment significantly attenuated the intracellular calcium accumulation from 126.7% (control) to 91.61% and 72.89% in 125 μg/ml and 250 μg/ml DG-treated groups, respectively (p < 0.001) and to 78.55% in KB-R7943- treated groups (p < 0.001) (Figure 7B).
DG has been reported to have a wide range of pharmacological properties, such as vasodilation, anti-atherosclerosis and an anti-oxidative effect[29–33, 37, 38]. Most particularly, DG pretreatment induced cardioprotection against an I/R injury in rats by enhancing the mitochondrial antioxidant status by activating PKCε to inhibit the opening of KATP in mitochondria[31, 32]. Our present study aims to explore whether the administering of DG post-treatment in the reperfusion/reoxygenation phase can directly provide protective effects against reperfusion injury ex vivo and in vitro. It was found that DG could protect the rat heart damage in the reperfusion phase by inhibiting the release of heart specific enzymes and restoring the contractile force as well as coronary flow rate recovery. In addition, DG directly and rapidly attenuated intracellular Ca2+ accumulation within H9c2 cells in the reoxygenation phase. DG also could inhibit the apoptosis of H9c2 cells. Our results provided evidence that there is a potential for patients with coronary heart diseases to attenuate the I/R injury in their blood restore surgeries by DG.
In our previous study, the contents of seven components, namely danshensu, protocatechuic aldehyde, puerarin, daidzein 8-capiosyl-glucoside, daidzin, salvianolic acid B and daidzein were quantified in DG water extract. Since only water extract was used, the valuable lipophilic tanshinones (cryptotanshinone, tanshinone I and tanshinone IIA) were not present in the DG extract or only in traces. Therefore, tanshinones did not contribute but water soluble marker such as salvianolic acid B might contribute to the cardiovascular protective activities.
In the ex vivo study, the recovery of coronary flow rate and of the contractile force in the reperfusion phase was examined. Oxygen delivery in the heart is dependent on two crucial factors, namely, the blood flow rate and the arterial oxygen content. Flow rate recovery could be helpful for restoring oxygen and nutrient supply and in the recovery of the heart function. In the present study, DG post-treatment obviously improved the coronary flow rate and contractile force recovery after an I/R challenge in a dose-dependent manner. In the high dosage DG treatment group, the contractile force recovery of the damaged heart was up to 60% (Figure 1A) and the coronary flow rate was almost totally recovered (Figure 1B). DG treatment significantly inhibited CK and LDH release in the hearts (Figure 1C &1D). It reflected that heart damage status had been partly reversed and was consistent with the results of contractile force and coronary flow rate recovery.
An I/R challenge always results in cardiac dysfunction and cellular injury through inducing a calcium overload and destroying the contractile apparatus (Troponin I, a membrane skeleton protein)[41, 42]. In the cellular model, it was found that membrane integrity of cardiomyocytes was protected by DG decoction by improving the expression of Troponin I (Figure 3). It underlines that DG post-treatment could restore the heart contraction function after an I/R challenge, by protecting the cell structure and the contractile unit integrity of cardiomyocytes. Additionally, DG treatment improved the survival of H9c2 cells after a H/R challenge (Figure 2). Figure 4 showed that the number of early apoptotic cells was obviously decreased after DG treatment. A high concentration of DG also significantly inhibited the late apoptosis of H9c2 cells. Inhibition of apoptosis was also examined by measuring the expression of pro-apoptosis and anti-apoptosis protein. The result showed that the expression of caspase 3 (pro-apoptotic factor) was significantly decreased and bcl 2 (anti-apoptotic factor) was significantly increased with DG treatment (Figure 5A). The increased survival ability of cardiomyocytes could improve the heart function recovery after an I/R challenge.
Over recent years, mitochondria have become a major research focus for experimental cardiologists. The exploration of the potential role of mitochondria in the pathogenesis of cardiovascular diseases, particularly in an I/R injury, has been greatly increased[43–45]. The opening of mPTP in the outer-membrane of mitochondria is a key pathological phenomenon involving in an I/R injury. One of its downstream events is the rupture of the outer mitochondrial membrane, which could become permeable to molecules smaller than 1.5 kDa, and which then would induce the release of cytochrome c. It is well known that when cyotochrome c is released from mitochondria, this could couple with Apaf-1, forming a macromolecular complex which recruits and activates the death effector caspase 9. The activated caspase 9 then activates caspase 3 and caspase 7, which in turn activates the early apoptosis process. To further investigate the molecular mechanism of anti-apoptotic activity of DG, the nature of the cytochrome c release after a H/R challenge was determined. Figure 5B showed that DG suppressed the release of cytochrome c from mitochondria to cytosol by comparing its expression between cytosol and mitochondria. The other event is the opening mPTP which causes mitochondria to become depolarized and loses its Δψ. This event is involved in early apoptosis and further induce the proton and other molecules going out of the outer mitochondrial membrane[44, 46]. Figure 6 showed that DG suppressed the mitochondrial depolarization of H9c2 in a dose-dependent manner. The results implied that DG could provide anti-apoptotic protection to the cardiomyocytes through inhibiting the opening of mPTP induced by a H/R injury. This is consistent with the previous report that pretreatment of DG inhibited the opening of MPT pores on rat hearts with an I/R challenge[20, 21].
Calcium ion stunning also plays a critical role in the initiation of apoptosis in cardiomyocyte in an I/R injury. Our present results revealed that DG treatment greatly inhibited a H/R-induced elevation of cytosolic calcium ion level through living cell recording system under the confocal microscope (Figure 7). The results suggested that the protection by DG may be mediated partly by decreasing the calcium influx into H9c2 cells. As a result, DG may improve the heart function recovery in an I/R Langendorff model by inhibiting the calcium overload within cardiomyocytes. Under an I/R or H/R situation, an ATP lack could induce the sodium overload caused by inhibition of the sarcolemmal Na+-K+-ATPase and calcium pump[51, 52]. The sodium overload would cause calcium overload via increased Na+-Ca2+ exchange in the reperfusion injury. This revealed the fact that DG may suppress the calcium overload to improve the heart function recovery by protecting the activity of Na+-K+-ATPase, calcium pump and Na+-Ca2+ exchanger. Our present result is consistent with a previous report that water extract of Danshen attenuated anoxia and reoxygenation-induced [Ca2+ i increase in rat cardiac ventricular myocytes and that DG pretreatment decreased the calcium concentration in the rat heart tissue with an I/R injury.
A limitation of this study is the use of ex vivo model instead of in vivo model. The reason is that the animal model of myocardial infarction (MI) which is mimicked by Langendorff heart model, is facing the high mortality rate of the surgical procedure. In brief, after anaesthesia, orotracheal intubation and thoracotomy, the heart is rapidly exteriorised and the coronary artery is ligated in the proximal segment using a thin thread. The occlusion of the artery can be recognised by blanching of the tissue distal to the ligation. In this complicated surgical procedures, a comparative study showed that the mortality of MI in Sprague–Dawley rats was 36%. Therefore, ex vivo Langendorff heart model was used in this study instead of in vivo model.
In conclusion, our study firstly demonstrated protection of DG post-treatment against the hypoxic rat cardiomyocytes (H9c2) and ischemic rat hearts from reperfusion injury. The cytoprotection of DG was associated with a decrease in calcium accumulation within H9c2 cells. DG improved H9c2 cell survival, protected the integrity of cell membrane skeleton, decreased the mitochondrial depolarization, decreased proapoptotic and increased anti-apoptotic protein in a dose-dependent manner. In the animal study, DG post-treatment at the reperfusion phase promoted their function recovery and inhibited heart specific enzyme release from a damaged heart. Our results suggested that DG may be a potential supplement for protecting coronary heart disease patients from clinical or spontaneous reperfusion injuries.
Levick JR: An introduction to cardiovascular physiology. 2003, London, UK: Oxford University Press Inc, Fourth edn
Bers DM: Excitation-contraction coupling and cardiac contractile force. 2001, Dordrecht: Kluwer
Chien KR, Han A, Sen A, Buja LM, Willerson JT: Accumulation of unesterified arachidonic acid in ischemic canine myocardium. Relationship to a phosphatidylcholine deacylation-reacylation cycle and the depletion of membrane phospholipids. Circ Res. 1984, 54 (3): 313-322. 10.1161/01.RES.54.3.313.
Shug AL, Thomsen JH, Folts JD, Bittar N, Klein MI, Koke JR, Huth PJ: Changes in tissue levels of carnitine and other metabolites during myocardial ischemia and anoxia. Arch Biochem Biophys. 1978, 187 (1): 25-33. 10.1016/0003-9861(78)90003-6.
Akabas MH: Na+/Ca2+ exchange inhibitors: potential drugs to mitigate the severity of ischemic injury. Mol Pharmacol. 2004, 66 (1): 8-10. 10.1124/mol.104.000232..
Pierce GN, Czubryt MP: The contribution of ionic imbalance to ischemia/reperfusion-induced injury. J Mol Cell Cardiol. 1995, 27 (1): 53-63. 10.1016/S0022-2828(08)80007-7.
Schafer C, Ladilov Y, Inserte J, Schafer M, Haffner S, Garcia-Dorado D, Piper HM: Role of the reverse mode of the Na+/Ca2+ exchanger in reoxygenation-induced cardiomyocyte injury. Cardiovasc Res. 2001, 51 (2): 241-250. 10.1016/S0008-6363(01)00282-6.
Lewandrowski K, Chen A, Januzzi J: Cardiac markers for myocardial infarction. A brief review. Am J Clin Pathol. 2002, 118 (Suppl): S93-S99.
Bocalini DS, Santos L, Antonio EL, Santos AA, Davel AP, Rossoni LV, Vassalo DV, Tucci PJ: Myocardial remodeling after large infarcts in rat converts post rest-potentiation in force decay. Arq Bras Cardiol. 2012, 98 (3): 243-251. 10.1590/S0066-782X2012005000016.
Mohan IK, Khan M, Wisel S, Selvendiran K, Sridhar A, Carnes CA, Bognar B, Kalai T, Hideg K, Kuppusamy P: Cardioprotection by HO-4038, a novel verapamil derivative, targeted against ischemia and reperfusion-mediated acute myocardial infarction. Am J Physiol Heart Circ Physiol. 2009, 296 (1): H140-H151.
Lefer DJ, Granger DN: Oxidative stress and cardiac disease. Am J Med. 2000, 109 (4): 315-323. 10.1016/S0002-9343(00)00467-8.
Hoffman JW, Gilbert TB, Poston RS, Silldorff EP: Myocardial reperfusion injury: etiology, mechanisms, and therapies. J Extra Corpor Technol. 2004, 36 (4): 391-411.
Murphy E, Steenbergen C: Mechanisms underlying acute protection from cardiac ischemia-reperfusion injury. Physiol Rev. 2008, 88 (2): 581-609. 10.1152/physrev.00024.2007.
Zucchi R, Ghelardoni S, Evangelista S: Biochemical basis of ischemic heart injury and of cardioprotective interventions. Curr Med Chem. 2007, 14 (15): 1619-1637. 10.2174/092986707780831014.
Zweier JL, Talukder MA: The role of oxidants and free radicals in reperfusion injury. Cardiovasc Res. 2006, 70 (2): 181-190. 10.1016/j.cardiores.2006.02.025.
Zorov DB, Juhaszova M, Sollott SJ: Mitochondrial ROS-induced ROS release: an update and review. Biochim Biophys Acta. 2006, 1757 (5–6): 509-517.
Huang T, Shi C: Zhong yao fang ji xian dai yan jiu da dian. 1996, Beijing: Ke xue chu ban she, 1
Chan K, Chui SH, Wong DY, Ha WY, Chan CL, Wong RN: Protective effects of Danshensu from the aqueous extract of Salvia miltiorrhiza (Danshen) against homocysteine-induced endothelial dysfunction. Life Sci. 2004, 75 (26): 3157-3171. 10.1016/j.lfs.2004.06.010.
Kamata K, Iizuka T, Nagai M, Kasuya Y: Endothelium-dependent vasodilator effects of the extract from Salviae Miltiorrhizae radix. A study on the identification of lithospermic acid B in the extracts. Gen Pharmacol. 1993, 24 (4): 977-981. 10.1016/0306-3623(93)90176-X.
Liu GT, Zhang TM, Wang BE, Wang YW: Protective action of seven natural phenolic compounds against peroxidative damage to biomembranes. Biochem Pharmacol. 1992, 43 (2): 147-152. 10.1016/0006-2952(92)90271-J.
Ji XY, Tan BKH, Zhu YC, Linz W, Zhu YZ: Comparison of cardioprotective effects using ramipril and DanShen for the treatment of acute myocardial infarction in rats. Life Sci. 2003, 73 (11): 1413-1426. 10.1016/S0024-3205(03)00432-6.
Sun J, Huang SH, Tan BK, Whiteman M, Zhu YC, Wu YJ, Ng Y, Duan W, Zhu YZ: Effects of purified herbal extract of Salvia miltiorrhiza on ischemic rat myocardium after acute myocardial infarction. Life Sci. 2005, 76 (24): 2849-2860. 10.1016/j.lfs.2004.11.016.
Zhao BL, Jiang W, Zhao Y, Hou JW, Xin WJ: Scavenging effects of salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury. Biochem Mol Biol Int. 1996, 38 (6): 1171-1182.
Cao ZL, Li JP, Zhang DM: Advances in the studies of isflavonoids in medicinal plants of Pueraria species. Zhong Yao Cai. 2005, 28: 67-71.
Li G, Zhang Q, Wang Y: Chemical constituents from roots of Pueraria lobata. Zhongguo Zhong Yao Za Zhi. 2010, 35 (23): 3156-3160.
Choo MK, Park EK, Yoon HK, Kim DH: Antithrombotic and antiallergic activities of daidzein, a metabolite of puerarin and daidzin produced by human intestinal microflora. Biol Pharm Bull. 2002, 25 (10): 1328-1332. 10.1248/bpb.25.1328.
Hintz KK, Ren J: Phytoestrogenic isoflavones daidzein and genistein reduce glucose-toxicity-induced cardiac contractile dysfunction in ventricular myocytes. Endocr Res. 2004, 30 (2): 215-223. 10.1081/ERC-120037730.
Yan LP, Chan SW, Chan AS, Chen SL, Ma XJ, Xu HX: Puerarin decreases serum total cholesterol and enhances thoracic aorta endothelial nitric oxide synthase expression in diet-induced hypercholesterolemic rats. Life Sci. 2006, 79 (4): 324-330. 10.1016/j.lfs.2006.01.016.
Tam WY, Chook P, Qiao M, Chan LT, Chan TYK, Poon YK, Fung KP, Leung PC, Woo KS: The efficacy and tolerability of adjunctive alternative herbal medicine (salvia miltiorrhiza and pueraria lobata) on vascular function and structure in coronary patients. J Altern Complem Med. 2009, 15 (4): 415-421. 10.1089/acm.2008.0400.
Koon CM, Woo KS, Leung PC, Fung KP: Salviae miltiorrhizae radix and puerariae lobatae radix herbal formula mediates anti-atherosclerosis by modulating key atherogenic events both in vascular smooth muscle cells and endothelial cells. J Ethnopharmacol. 2011, 138 (1): 175-183. 10.1016/j.jep.2011.08.073.
Chiu PY, Wong SM, Leung HY, Leong PK, Chen N, Zhou LM, Zuo Z, Lam PY, Ko KM: Long-term treatment with danshen-gegen decoction protects the myocardium against ischemia/reperfusion injury via the redox-sensitive protein kinase C-epsilon/mK(ATP) pathway in rats. Rejuv Res. 2011, 14 (2): 173-184. 10.1089/rej.2010.1094.
Chiu PY, Wong SM, Leung HY, Leong PK, Chen N, Zhou LM, Zuo Z, Lam PY, Ko KM: Acute treatment with Danshen-Gegen decoction protects the myocardium against ischemia/reperfusion injury via the redox-sensitive PKC epsilon/mK(ATP) pathway in rats. Phytomedicine. 2011, 18 (11): 916-925. 10.1016/j.phymed.2011.03.006.
Lam FF, Deng SY, Ng ES, Yeung JH, Kwan YW, Lau CB, Koon JC, Zhou L, Zuo Z, Leung PC: Mechanisms of the relaxant effect of a danshen and gegen formulation on rat isolated cerebral basilar artery. J Ethnopharmacol. 2010, 132 (1): 186-192. 10.1016/j.jep.2010.08.015.
Sagach VF, Scrosati M, Fielding J, Rossoni G, Galli C, Visioli F: The water-soluble vitamin E analogue Trolox protects against ischaemia/reperfusion damage in vitro and ex vivo. A comparison with vitamin E. Pharmacol Res. 2002, 45 (6): 435-439. 10.1006/phrs.2002.0993.
Chang WT, Shao ZH, Yin JJ, Mehendale S, Wang CZ, Qin Y, Li J, Chen WJ, Chien CT, Becker LB: Comparative effects of flavonoids on oxidant scavenging and ischemia-reperfusion injury in cardiomyocytes. Eur J Pharmacol. 2007, 566 (1–3): 58-66.
Budinger GR, Duranteau J, Chandel NS, Schumacker PT: Hibernation during hypoxia in cardiomyocytes. Role of mitochondria as the O2 sensor. J Biol Chem. 1998, 273 (6): 3320-3326. 10.1074/jbc.273.6.3320.
Sieveking DP, Woo KS, Fung KP, Lundman P, Nakhla S, Celermajer DS: Chinese herbs Danshen and Gegen modulate key early atherogenic events in vitro. Int J Cardiol. 2005, 105 (1): 40-45. 10.1016/j.ijcard.2004.10.052.
Ng CF, Koon CM, Cheung DW, Lam MY, Leung PC, Lau CB, Fung KP: The anti-hypertensive effect of Danshen (Salvia miltiorrhiza) and Gegen (Pueraria lobata) formula in rats and its underlying mechanisms of vasorelaxation. J Ethnopharmacol. 2011, 137 (3): 1366-1372. 10.1016/j.jep.2011.08.006.
Wagner H, Bauer R, Melchart D, Xiao PG, Staudinger A: Chromatographic fingerprint analysis of herbal medicines. 2011, Springer Wien New York, 903-921. 2
Acierno LJ: Adolph Fick: mathematician, physicist, physiologist. Clin Cardiol. 2000, 23 (5): 390-391. 10.1002/clc.4960230519.
Hensley K, Robinson KA, Gabbita SP, Salsman S, Floyd RA: Reactive oxygen species, cell signaling, and cell injury. Free Radic Biol Med. 2000, 28 (10): 1456-1462. 10.1016/S0891-5849(00)00252-5.
Tanasijevic MJ, Cannon CP, Wybenga DR, Fischer GA, Grudzien C, Gibson CM, Winkelman JW, Antman EM, Braunwald E: Myoglobin, creatine kinase MB, and cardiac troponin-I to assess reperfusion after thrombolysis for acute myocardial infarction: results from TIMI 10A. Am Heart J. 1997, 134 (4): 622-630. 10.1016/S0002-8703(97)70044-9.
Loor G, Kondapalli J, Iwase H, Chandel NS, Waypa GB, Guzy RD, Vanden Hoek TL, Schumacker PT: Mitochondrial oxidant stress triggers cell death in simulated ischemia-reperfusion. Biochim Biophys Acta. 2011, 1813 (7): 1382-1394. 10.1016/j.bbamcr.2010.12.008.
Aon MA, Cortassa S, O’Rourke B: Mitochondrial oscillations in physiology and pathophysiology. Adv Exp Med Biol. 2008, 641: 98-117.
Akar FG, Aon MA, Tomaselli GF, O’Rourke B: The mitochondrial origin of postischemic arrhythmias. J Clin Invest. 2005, 115 (12): 3527-3535. 10.1172/JCI25371.
Honda HM, Ping P: Mitochondrial permeability transition in cardiac cell injury and death. Cardiovasc Drugs Ther. 2006, 20 (6): 425-432. 10.1007/s10557-006-0642-0.
Buki A, Okonkwo DO, Wang KK, Povlishock JT: Cytochrome c release and caspase activation in traumatic axonal injury. J Neurosci. 2000, 20 (8): 2825-2834.
Hu Y, Benedict MA, Ding L, Nunez G: Role of cytochrome c and dATP/ATP hydrolysis in Apaf-1-mediated caspase-9 activation and apoptosis. EMBO J. 1999, 18 (13): 3586-3595. 10.1093/emboj/18.13.3586.
Liu X, Kim CN, Yang J, Jemmerson R, Wang X: Induction of apoptotic program in cell-free extracts: requirement for dATP and cytochrome c. Cell. 1996, 86 (1): 147-157. 10.1016/S0092-8674(00)80085-9.
Brookes PS, Yoon Y, Robotham JL, Anders MW, Sheu SS: Calcium, ATP, and ROS: a mitochondrial love-hate triangle. Am J Physiol Cell Physiol. 2004, 287 (4): C817-C833. 10.1152/ajpcell.00139.2004.
Dixon IM, Hata T, Dhalla NS: Sarcolemmal Na(+)-K(+)-ATPase activity in congestive heart failure due to myocardial infarction. Am J Physiol. 1992, 262 (3 Pt 1): C664-C671.
Dixon IM, Kaneko M, Hata T, Panagia V, Dhalla NS: Alterations in cardiac membrane Ca2+ transport during oxidative stress. Mol Cell Biochem. 1990, 99 (2): 125-133.
Cao CM, Xia Q, Zhang X, Xu WH, Jiang HD, Chen JZ: Salvia miltiorrhiza attenuates the changes in contraction and intracellular calcium induced by anoxia and reoxygenation in rat cardiomyocytes. Life Sci. 2003, 72 (22): 2451-2463. 10.1016/S0024-3205(03)00142-5.
Liu YH, Yang XP, Nass O, Sabbah HN, Peterson E, Carretero OA: Chronic heart failure induced by coronary artery ligation in Lewis inbred rats. Am J Physiol. 1997, 272: H722-H727.
The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/12/249/prepub
We would like to thank Dr. Wilmshurst, CUHK, for editing the English language of our manuscript. This work was supported by the State Key laboratory of Phytochemistry and Plant Resources western China (CUHK) and a grant from the Institute of Chinese Medicine (UGC-Area of Excellence Project, AoE/B-10/01).
The authors declare that they have no competing interests.
FH was responsible for performing the experiments, analyzing the data and drafting the manuscript. K-PF, C-MK and JY-WC supervised the whole study and revised the manuscript. All authors have read and approved the final manuscript.
Authors’ original submitted files for images
Below are the links to the authors’ original submitted files for images.
Rights and permissions
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Hu, F., Koon, CM., Chan, J.YW. et al. The cardioprotective effect of danshen and gegen decoction on rat hearts and cardiomyocytes with post-ischemia reperfusion injury. BMC Complement Altern Med 12, 249 (2012). https://doi.org/10.1186/1472-6882-12-249
- Danshen and Gegen decoction
- Ischemia and reperfusion
- Hypoxia and reoxygenation